TG THERAPEUTICS, INC. updated its the three months ended March 31, 2026 guidance (raised).
“On May 6, 2026, the Company issued a press release announcing results of operations for the three months ended March 31, 2026.”
TG THERAPEUTICS, INC. — fact timeline
Source-grounded facts extracted from TG THERAPEUTICS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
TG THERAPEUTICS, INC. incurred term loan of $750 million with Blue Owl Capital Corporation at an applicable margin plus, at the Borrower’s option, either (a) a base rate dete maturing March 18, 2031.
“the Borrower established (i) a $750 million term loan facility (the “2026 Term Loan”), which was borrowed in full on the Closing Date”
TG THERAPEUTICS, INC. amended First Amendment with Blue Owl Capital Corporation, as administrative agent, and the lenders party thereto valued at $750 million term loan facility (effective 2026-03-18).
“On March 18, 2026 (the “Closing Date”), the Company (the “Borrower”) entered into the first amendment agreement, dated as of the Closing Date (the “First Amendment”), by and among the Borrower, certain subsidiaries of the Borrower, as guarantors, the lenders party thereto and Blue Owl Capital Corporation, as administrative agent (the “Administrative Agent”), which amends the financing agreement, dated as of August 2, 2024”
TG THERAPEUTICS, INC. updated its the three months ended March 31, 2024 guidance (raised).
“On May 1, 2024, TG Therapeutics, Inc. (the “Company”) issued a press release announcing results of operations for the three months ended March 31, 2024.”
TG THERAPEUTICS, INC. updated its the fourth quarter and year ended December 31, 2023 guidance (raised).
“On February 28, 2024, TG Therapeutics, Inc. (the “Company”) issued a press release announcing results of operations for the three and twelve months ended December 31, 2023.”
TG THERAPEUTICS, INC. entered into License Agreement with Precision BioSciences, Inc. valued at $7.5 million (effective 2024-01-07).
“On January 7, 2024, TG Therapeutics, Inc. (the “Company”) and its wholly-owned subsidiary, TG Cell Therapy, Inc., entered into a License Agreement (the “License Agreement”) with Precision BioSciences, Inc. (“Precision”), pursuant to which Precision granted the Company certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize Precision’s allogeneic CAR T therapy azercabtagene zapreleucel (“azer-cel”) for the treatment of autoimmune and other non-oncology diseases and conditions (collectively, the “Field”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.